Home Biosimilar Antibodies Cytoskeletal Signaling Integrin Vedolizumab (anti-α4β7-integrin)
For research use only. Not for use in humans.

Vedolizumab (anti-α4β7-integrin)

Synonyms: LPAM-1， Integrin alpha4beta7

Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.

Vedolizumab (anti-α4β7-integrin)

Click to purchase the isotype control of Vedolizumab (anti-α4β7-integrin)

Quality Control

Batch: A204502 Purity: 98% Protein concentration: 5.72mg/ml Endotoxin Level: ＜1EU/mg
98

Specificity

Name Citation Integrin ILK Others
Cilengitide trifluoroacetate 71
A-205804 7
GLPG0187 1
GSK-3008348 HCl 0
Bexotegrast (PLN-74809) 1
Cilengitide (EMD 121974) 37
OSU-T315 1
TR-14035 0
Cyclo(RGDyK) TFA 15
SB273005 27
RGD peptide (Arg-Gly-Asp) 27
ILK-IN-3 1
RGD peptide (GRGDNP) 5 caspase-3
ATN-161 22
Cyclo(-RGDfK) TFA 14
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
In vitro

Vedolizumab (anti-α4β7-integrin) binds to a subset of human peripheral blood memory CD4+ T lymphocytes including gut-homing interleukin 17 T-helper lymphocytes at the highest level, also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels; Vedolizumab binds to memory CD4+ T and B lymphocytes with subnanomolar potency with EC50 of 0.3-0.4 nM.
Cell Research

PBMCs were resuspended in assay buffer for CD4 memory cell interleukin (IL) 17A intracellular staining. PBMCs were stimulated (or not stimulated, for the control samples) with 50 ng/ml phorbol 12-myristate 13-acetate and 1 µg/ml Ionomycin in the presence of 3 µM Monensin for 5 h at 37°C. After washing, cells were stained with fluorescent-labeled antibodies: vedolizumab, anti-α4 and anti-β7, anti-CD4, and anti-CD45RO, where applicable, at 4°C for 30 min. Cells were then washed with cold PBS and resuspended in fixation and permeabilization working solution staining buffer at 4°C for 30 min. After fixation and permeabilization, cells were washed with permeabilization buffer and blocked with 10% normal rat serum at 4°C for 10 min. After the blocking step, cells were stained with fluorochrome-conjugated anti_x0002_IL17A antibody at 4°C for 30 min. Finally, cells were washed with permeabilization buffer and analyzed.
References

Product Details

CAS No. 943609-66-3
Molecular Weight 145.7 KD
Isotype Human IgG1
Application Vedolizumab (anti-α4β7-integrin)
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05442567 RECRUITING Drug: Vedolizumab IV Ulcerative Colitis; Crohn's Disease Takeda 2023-05-16 PHASE3
NCT06337695 RECRUITING IrAE; Immune-related Adverse Event; Diarrhea; Colitis AHS Cancer Control Alberta 2026-08-13 PHASE2; PHASE3
NCT06405087 RECRUITING Drug: Vedolizumab SC Ulcerative Colitis; Crohn's Disease Takeda 2025-10-27 PHASE3
NCT07576452 NOT_YET_RECRUITING Drug: 1: infliximab 2: filgotinib 3: ustekinumab 4: vedolizu Ulcerative Colitis (UC) University Hospital, Clermont-Ferrand 2026-06-01 PHASE4
NCT05837897 RECRUITING Drug: Vedolizumab IV|Drug: Placebo Crohn's Disease Takeda 2023-06-16 PHASE3
NCT06443502 RECRUITING Drug: Vedolizumab|Drug: Concomitant Antibiotic Therapy Pouchitis Takeda 2024-11-19 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-05-07)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.